Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 Days Payable is 35.91 as of Mar. 2026, which is 6% above its 10-year median of 33.96. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 926 Drug Manufacturers companies, Speciality Medicines ranks worse than 59.94% on this metric.
The historical data trend for Speciality Medicines's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines Days Payable Chart
Speciality Medicines Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
Days Payable
12.32
33.96
42.28
14.65
43.45
Speciality Medicines Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
Days Payable
0.00
0.00
0.00
13.48
35.91
BOM:544738 vs ZTS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's Days Payable distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Speciality Medicines's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines (BOM:544738) has a Days Payable of 35.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Speciality Medicines and its competitors. This is near median its historical median of 33.96. Over the past decade, Speciality Medicines' Days Payable has ranged from 12.32 to 71.82. According to the industry distribution chart, Speciality Medicines ranks #555 out of 926 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Speciality Medicines' Days Payable too high?
Speciality Medicines' current Days Payable of 35.91 is near median its 10-year median of 33.96. Over the past 10 years, this metric has ranged from a low of 12.32 to a high of 71.82. The Drug Manufacturers industry median Days Payable is 89.98. Speciality Medicines' value of 35.91 is 60.1% below this industry median. Based on the distribution chart, Speciality Medicines ranks #555 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #555 out of 926 companies for Days Payable. This places Speciality Medicines in the lower half of its industry. The industry median Days Payable is 89.98. Speciality Medicines' value of 35.91 is 60.1% below this benchmark. Historically, Speciality Medicines' own Days Payable has ranged from 12.32 to 71.82 over the past decade. While the company's 10-year median is 33.96 vs. the industry median of 89.98, Speciality Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.98, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current Days Payable of 35.91 is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Speciality Medicines and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current Days Payable is 35.91, which is near median its own 10-year median of 33.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current Days Payable of 35.91. The current Days Payable is 35.91, which is near median its 10-year median of 33.96 and 60.1% below the Drug Manufacturers industry median of 89.98. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current Days Payable is 35.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
